Document › Details
Boehringer Ingelheim. (1/15/15). "Press Release: 35 Partners from Industry and Academia to Join European Research Initiative for the Prevention of Alzheimer’s Dementia". Paris.
|Region||EU (European Union)|
|Organisation||Boehringer Ingelheim (Group)|
|Organisation 2||EPAD project (European Prevention of Alzheimer’s Dementia Initiative) (IMI, EU, EFPIA 201501–)|
|Product 2||Alzheimer drug|
|Person||Van der Geyten, Serge (JnJ 201501 Director for Neuroscience External Affairs at Janssen Pharmaceutica NV)|
> The European Prevention of Alzheimer’s dementia (EPAD) Initiative is a collaborative research initiative to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops.
> The 5 year EPAD programme is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.
> EPAD will establish a European-wide register of 24,000 participants, of which 1,500 will be invited to participate in a trial to test new treatments for prevention of Alzheimer’s dementia
The members of the EPAD initiative today announced the start of a novel collaboration between academic and private sectors to test innovative treatments for the prevention of Alzheimer’s dementia.
Previous attempts to bring new drugs for Alzheimer’s disease to the market have been disappointing despite a high level of investment. However, the realisation that Alzheimer’s disease is a progressive disorder and that early intervention may be more effective has led to research efforts being focused on prevention. The goal of the initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities as identified by specific tests), who still may have little or no complaints or clinical symptoms.
"EPAD is part of a global initiative that will make a fundamental difference to the understanding and management of Alzheimer’s disease in people with very early or no symptoms at all. This could be a game-changer. It is only possible because of the absolute commitment of academics, industry, policy makers and the public to work hand in hand to defeat this global threat", said Prof Craig Ritchie, EPAD Co-coordinator and Professor of the Psychiatry of Ageing at the University of Edinburgh.
New tools and methods now allow the identification of patients in the early stages of Alzheimer’s disease. This creates an opportunity to have new treatment options investigated in clinical studies early on. A difficulty however remains with the large number of patients and study sites needed to confirm a therapeutic effect within a limited span of time. In contrast to several pharmaceutical companies and academic institutions pursuing this in isolation, a joint effort clearly has advantages: the identification and referral of the concerned patients is accelerated and several treatment options can be tested rapidly within one same trial.
Therefore, EPAD aims to develop a platform using existing information from national or regional patient cohorts or register studies, which have already identified potential patients. Through EPAD, the undertaking of better, adaptive, multi-arm proof of concept studies for early and accurate decisions on the ongoing development of drug candidates or drug combinations is facilitated.
"Preventing the development of dementia in biomarker-positive people would be a fantastic step forward in our fight against Alzheimer’s disease. The EPAD and its novel trial concept will hopefully help speed up the drug discovery progress and bring us closer to this ambitious aim", said Jean Georges, Executive Director of Alzheimer Europe.
All data collected from the cohort and trial will become publically available for analysis to improve disease models in the pre-dementia phase of Alzheimer’s disease.
"This project has numerous advantages over current approaches. These include the excellent pre-trial characterisation of subjects to inform selection and reduce screen failure, the establishment of the highest possible quality study sites across Europe, the rapid decision making on the likely success of a drug (or combination of drugs) in subsequent confirmatory trials as well as access to a shared placebo group.", said Serge Van der Geyten, EPAD Coordinator and Director for Neuroscience External Affairs at Janssen Pharmaceutica NV.
About Alzheimer’s disease and dementia
Alzheimer’s disease is a progressive degenerative disease which causes loss of neurons in the brain. The symptoms eventually and inevitably manifest as Alzheimer’s dementia which impacts cognition, function and behaviour, becomes progressively worse over time and cannot be reversed. There are 7.7 million new cases of dementia globally each year, suggesting one new case every four seconds. There were an estimated 44.4 million people with dementia in 2013 and this number is estimated to increase to 135.5 million by 2050. Currently approved treatments may temporarily stabilise or slow the worsening of symptoms, but do not alter the course of the disease. Attempts to bring new drugs to market for the treatment and prevention of Alzheimer’s dementia have been disappointing despite massive commercial, public and academic investment of time and resources.
The EPAD project is part of a global effort in the fight against Alzheimer’s disease, which also includes initiatives such as the Global Alzheimer Platform. The EPAD Project is a major European initiative to create a novel environment for testing numerous interventions targeted at the prevention of Alzheimer’s dementia defined as a delay in the onset of clinical symptoms among people with preclinical evidence for AD pathology (i.e. preclinical AD as per NIA-AA and similar definitions) and a delay in the onset of clinical dementia among people with such evidence who already show some clinical symptoms (ie MCI due to AD or prodromal AD and similar definitions).
EPAD is mainly sponsored by the European Commission and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative Joint Undertaking (IMI JU). The EPAD programme has an initial budget of €64M distributed across a total of 35 partners from the private and academic sectors:
• Janssen Pharmaceutica NV, Belgium
• University of Edinburgh, United Kingdom
• University of Oxford, United Kingdom
• Barcelonabeta Brain research Centre, Spain
• Synapse Research Management Partners SL, Spain
• Karolinska Institutet, Center For Alzheimer Disease Research, Sweden
• Stichting VU-VUmc, Netherlands
• University of Cambridge, United Kingdom
• Medical Research Council Biostatistics Unit, United Kingdom
• Berry Consultants LLP, United Kingdom
• Université de Genève, Switzerland
• Radboud University Medical Centre, Netherlands
• Cardiff University, United Kingdom
• Centre Hospitalier Universitaire de Toulouse, France
• Quintiles, LTD, United Kingdom
• Alzheimer Europe, Luxembourg
• Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
• Hôpital de la Salpêtrière, France
• Institut national de la santé et de la recherche médicale, France
• University of Leicester, United Kingdom
• IXICO Technologies Ltd, United Kingdom
• Araclon Biotech, S.L., Spain
• Fraunhofer, Germany
• Eisai Inc., United States
• Sanofi-Aventis Recherche & Développement, France
• Novartis Pharma AG, Switzerland
• Boehringer Ingelheim International GmbH, Germany
• Ely Lilly and Company Ltd, United Kingdom
• Lundbeck A/S, Denmark
• Takeda Development Centre Europe Ltd, United Kingdom
• AC Immune SA, Switzerland
• Biogen Idec Inc., United States
• Amgen NV, Belgium
• Pfizer Limited, United Kingdom
• UCB Biopharma SPRL, Belgium
The project is divided into eight Work Packages with four Scientific Advisory Groups. The trial will be delivered through approximately 30 study sites within six country/regional areas.
While the EPAD platform will be designed to help testing both pharmacological and non-pharmacological interventions, initially the focus will be on testing drugs and drug combinations to ensure a greater chance of success for clinical trials. The EPAD programme will initially run for five years.
For more information, contact email@example.com or check out www.ep-ad.org
About the EPAD Platform/Register
EPAD aims to develop a platform using existing information. The EPAD platform will draw European participants, whose records are already part of existing national/regional cohort or register studies, into an EPAD register of approximately 24,000 people. From this group, 6,000 people will be asked to join a pan-European EPAD Cohort for consistent, longitudinal follow-up, and approximately 1,500 of them will eventually be invited to enter the EPAD Proof of Concept Trial. This approach aims to ensure EPAD has access to an at-risk population showing biomarker evidence of Alzheimer’s disease prior to the development of dementia.
About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.
More information can be found at www.imi.europa.eu
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.
This communication reflects the views of the EPAD Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Dr. Serge Van der Geyten
Director, Neuroscience External Affairs
Janssen Pharmaceutica NV
c/o Frederik Wittock
Senior Director R&D Communications
+32 476 92 50 77
+32 14 60 57 24
Prof. Craig Ritchie
Professor of the Psychiatry of Ageing
University of Edinburgh
c/o Anna Borthwick
University of Edinburgh Press & PR Office
+44-131-650 22 46
+32 14 60 57
Media & PR
Binger Strasse 173
55216 Ingelheim am Rhein
Phone +49/6132/77 82 71
Fax +49/6132/77 6601
Record changed: 2016-04-30
More documents for Boehringer Ingelheim (Group)
-  Boehringer Ingelheim. (2/16/17). "Press Release: US FDA Expands Approval of Tiotropium Respimat for Maintenance Treatment of Asthma in Children". Ingelheim....
-  Boehringer Ingelheim. (2/15/17). "Press Release: Boehringer Ingelheim and Weill Cornell Medicine Announce New Collaboration to Discover Next Generation COPD Treatments". Ingelheim....
-  Sanofi S.A.. (1/2/17). "Press Release: Sanofi and Boehringer Ingelheim Confirm Closing of Business Swap on January 1st 2017". Paris & Ingelheim....
-  Bayer AG. (12/7/16). "Press Release: Boehringer Ingelheim Vetmedica, Inc. and Bayer Enter into Agreement for Purchase of U.S. Cydectin Product Portfolio". Shawnee, KS....
-  Advanced Chemistry Development, Inc. (ACD/Labs). (11/30/16). "Press Release: Boehringer Ingelheim Selects ACD/Labs for International Deployment". Toronto, ON....
-  Biodesix, Inc.. (10/5/16). "Press Release: VeriStrat Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy". Boulder, CO....
-  Boehringer Ingelheim. (9/30/16). "Press Release: Boehringer Ingelheim Returns Development and Commercial Rights of Olmutinib to Hanmi Pharmaceutical". Ingelheim....
-  Boehringer Ingelheim. (9/29/16). "Press Release: Boehringer Ingelheim and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Immune-oncology Therapies". Ingelheim....
-  Boehringer Ingelheim. (9/28/16). "Press Release: Boehringer Ingelheim Boosts Immune-oncology Pipeline through Collaboration with ViraTherapeutics". Ingelheim....
-  Boehringer Ingelheim. (9/16/16). "Press Release: Glyxambi (empagliflozin/linagliptin) Approval Recommended by CHMP for Adults with Type 2 Diabetes in the European Union". Ingelheim & Indianapolis, IN....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)